Transdermal drug delivery systems (TDDS) are dosage forms designed to deliver a therapeutically effective amount of drug across a patient’s skin. In the current research Diltiazem hydrochloride was loaded in transdermal patch and they are prepared by solvent casting method using aluminum foil as the backing membrane. Eudragit RS100 and HPMC were weighed in requisite ratios and they were then dissolved in methanol as solvent using magnetic stirrer.Four optimized transdermal patches were formulated with different drug-polymer ratios. Diltiazem Hcl (20mg) was added into homogenous dispersion under slow stirring with a magnetic stirrer. Dibutyl phthalate 30%w/w of polymer composition was used as plasticizer, added to the above dispersion under ...
Reverse micelle transformation based liquid crystalline (TLC) transdermal gel of diltiazem hydrochlo...
AbstractIn the present study, gel formulations of organogels, hydrogels, and oleo-hydrogel (bigels) ...
ABSTRACTDiltiazem HCL is an antihypertensive that low oral bioavailability of 40%, so developed to t...
A significant effort was done to formulate transdermal patches (Paranjothi 1998) of Diltiazem Hydroc...
Present study deals with the formulation and characterization of matrix type transdermal drug delive...
ABSTRACT Diltiazem hydrochloride (diltiazem HCl), a calcium channel blocker is widely used in the m...
The purpose of this research was to develop and design a matrix-type transdermal therapeutic system ...
The conventional oral dosage forms have some drawbacks like poor bioavailability, first pass metabol...
The aim of this study was to develop transdermal patch of Atomoxetine hydrochloride which has good m...
The present study was aims to formulate and evaluate transdermal drug delivery for sustained release...
Diltiazem HCL is an antihypertensive that low oral bioavailability of 40%, so developed to transderm...
The present study was aims to formulate and evaluate transdermal drug delivery for sustained release...
Transdermal Drug Delivery System (TDDS) are topically administered medicaments that deliver drugs fo...
Transdermal drug delivery system (TDDS) was designed to sustain the release and improve the bioavail...
Purpose: To develop and optimise sustained release (SR) matrix tablets of diltiazem hydrochloride (D...
Reverse micelle transformation based liquid crystalline (TLC) transdermal gel of diltiazem hydrochlo...
AbstractIn the present study, gel formulations of organogels, hydrogels, and oleo-hydrogel (bigels) ...
ABSTRACTDiltiazem HCL is an antihypertensive that low oral bioavailability of 40%, so developed to t...
A significant effort was done to formulate transdermal patches (Paranjothi 1998) of Diltiazem Hydroc...
Present study deals with the formulation and characterization of matrix type transdermal drug delive...
ABSTRACT Diltiazem hydrochloride (diltiazem HCl), a calcium channel blocker is widely used in the m...
The purpose of this research was to develop and design a matrix-type transdermal therapeutic system ...
The conventional oral dosage forms have some drawbacks like poor bioavailability, first pass metabol...
The aim of this study was to develop transdermal patch of Atomoxetine hydrochloride which has good m...
The present study was aims to formulate and evaluate transdermal drug delivery for sustained release...
Diltiazem HCL is an antihypertensive that low oral bioavailability of 40%, so developed to transderm...
The present study was aims to formulate and evaluate transdermal drug delivery for sustained release...
Transdermal Drug Delivery System (TDDS) are topically administered medicaments that deliver drugs fo...
Transdermal drug delivery system (TDDS) was designed to sustain the release and improve the bioavail...
Purpose: To develop and optimise sustained release (SR) matrix tablets of diltiazem hydrochloride (D...
Reverse micelle transformation based liquid crystalline (TLC) transdermal gel of diltiazem hydrochlo...
AbstractIn the present study, gel formulations of organogels, hydrogels, and oleo-hydrogel (bigels) ...
ABSTRACTDiltiazem HCL is an antihypertensive that low oral bioavailability of 40%, so developed to t...